Safety and adverse event profile of duloxetine

Author： Wernicke Joachim F   Gahimer James   Yalcin Ilker   Wulster-Radcliffe Meghan   Viktrup Lars  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.4, Iss.6, 2005-11, pp. : 987-993

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The hepatic safety profile of duloxetine: a review

By McIntyre Roger S   Panjwani Zilomi D   Nguyen Ha T   Woldeyohannes Hanna O   Alsuwaidan Mohammad   Soczynska Joanna K   Lourenco Maria T   Konarski Jakub Z   Kennedy Sidney H  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 3, 2008-03 ,pp. : 281-285

Informa Healthcare

Access to resources Recommend Favorite

Profile of Adverse Events with Duloxetine Treatment: A Pooled Analysis of Placebo-Controlled Studies

By Brunton Stephen  

Drug Safety, Vol. 33, Iss. 5, 2010-05 ,pp. : 393-407

Adis International

Access to resources Recommend Favorite

Adverse-Event Profile of Crataegus Spp.: A Systematic Review

By Daniele Claudia  

Drug Safety, Vol. 29, Iss. 6, 2006-01 ,pp. : 523-535

Adis International

Access to resources Recommend Favorite

Safety Reporting and Adverse-Event Profile of Mirtazapine Described in Randomized Controlled Trials in Comparison with Other Classes of Antidepressants in the Acute-Phase Treatment of Adults with Depression: Systematic Review and Meta-Analysis

By Watanabe Norio  

CNS Drugs, Vol. 24, Iss. 1, 2010-01 ,pp. : 35-53

Adis International

Access to resources Recommend Favorite

Adverse event profile similar for drug-eluting and bare-metal stents

By  

Reactions Weekly, Vol. 1, Iss. 1170, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite